基因6a型丙型病毒性肝炎DAAs治疗失败后再治疗成功1例报道  

A case report of successful retreatment of gene 6a viral hepatitis C after DAAs treatment failure

作　　者：王晶[1] 袁琦 廖金卯[1] WANG Jing;YUAN Qi;LIAO Jinmao(Department of Hepatology,the First Affiliated Hospital of Hunan Normal University(Hunan People′s Hospital),Changsha 410005,China)

机构地区：[1][HT6K]湖南师范大学附属第一医院(湖南省人民医院)肝病内科,湖南长沙410005

出　　处：《胃肠病学和肝病学杂志》2025年第4期621-622,共2页Chinese Journal of Gastroenterology and Hepatology

基　　金：湖南省科技厅临床医疗技术创新引导项目(2021SK50910)。

摘　　要：丙型病毒性肝炎是由丙型肝炎病毒(hepatitis C virus,HCV)感染所致的疾病,目前仍是全球常见的感染性疾病之一。基因6型HCV在全球HCV基因型中占比逐年升高,在某些地区已成为主要基因类型,大多数经直接抗病毒药物(direct acting antivirals,DAAs)治疗可治愈,但仍有极小部分治疗失败的病例,本文现报道1例基因6a型丙型病毒性肝炎经2次DAAs治疗失败后使用DAAs联合利巴韦挽救治疗实现持续病毒学应答(sustained virological response,SVR),旨在为本病的治疗方案提供新参考和选择。Viral hepatitis C is a disease caused by hepatitis C virus(HCV)infection and is still one of the most common infectious diseases in the world.The proportion of HCV genotype 6 has been increasing year by year in the global HCV genotype,and it has become the main genotype in some regions.Most of the hepatitis C virus can be cured by direct acting antivirals(DAAs)treatment,but there are still a small number of cases of treatment failure.This paper reported a sustained virological response(SVR)achieved by DAAs combined with ribavir after two DAAs treatment failures in a case of genotype 6a viral hepatitis C.It aimed to provide a new reference and choice for the treatment of the disease.

关 键 词：慢性丙型肝炎 直接抗病毒药物 治疗失败 再治疗 

分 类 号：R575[医药卫生—消化系统]